腹腔热化疗治疗进展期胃癌生存分析  

Survival Analysis of Hyperthemic Intraperitoneal Chemotherapy on Progressive Gastric Cancer

作　　者：杨家梅[1] 梁冰[1] 韩娜[1] 

机构地区：[1]郑州大学第二附属医院肿瘤科,郑州市450003

出　　处：《医药论坛杂志》2004年第7期22-23,25,共3页Journal of Medical Forum

摘　　要：目的　探讨进展期胃癌姑息性切除后腹腔热化疗的价值。方法　将 6 8例姑息性切除后的进展期胃癌随机分为腹腔热化疗组 (治疗组 ) 34例 ,单纯全身静脉化疗组 (对照组 ) 34例。治疗组以顺铂 (DDP)、5 氟尿嘧啶 (5 Fu)腹腔热化疗 ,依托泊苷 (Vp 16 )全身静脉化疗 ;对照组以Vp 16、5 Fu、DDP联合静脉化疗 ,并观察记录疗效和不良反应。结果　治疗组 1年、2年的生存率分别为 85 2 %、5 0 0 % ;对照组 1年、2年生存率分别为5 8 8%、17 6 % ,治疗组的 1年、2年生存率明显高于对照组 (P <0 0 1) ,差异有显著性 ,治疗组不良反应低于对照组。结论　腹腔热化疗联合全身化疗疗效高 ,不良反应低 ,是进展期胃癌姑息性切除后较好的辅助治疗措施。Objective To assess the efficacy of hyperthemic intraperitoneal chemotherapy on advanced gastric cancer after palliative gastrectomy.Methods 68 cases of patients with advanced gastric cancer treated by palliative gastrectomy were selected and randomly divided into two groups Treatment group(34 cases) received Vp-16,5-FU,DDP systematic treatment plus DDP,5-FU hyperthemic intraperitoneal chemotherapy Control group(34 cases) received systemic chemotherapy, survival rate and side effect was recorded.Results The 1-year and 2-year survival rate for the hyperthemic intraperitoneal chemotherapy group were 85 2%、 50 0% while the control group were 58 8%,17 6%,the l-year and 2-year survival rate of treatment group is obviously higher than that of control group (P<0 01). The side reaction of treatment group is lower than that of control group.Conclusion Using systematic plus hyperthemic intraperitoneal chemotherapy in treating advanced gastric cancer after palliative gastrectomy is superior to systematic chemotherapy only.

关 键 词：治疗 进展期胃癌 姑息性切除术 腹腔热灌注化疗 静脉化疗 生存期 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]